Pomerantz investigates ClearPoint Neuro stock over September setback

Published on 10/14/2026 at 00:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pomerantz announced an investigation on October 13, 2026. ClearPoint Neuro stock fell 23.12 percent on September 29.

ClearPoint investigation and results

Pomerantz announced a securities investigation involving ClearPoint Neuro on October 13, 2026.
Second-quarter revenue reached USD 10.88 million, up 18.00 percent year over year.
ClearPoint Neuro stock fell 23.12 percent to USD 11.77 on September 29, 2026.
The next earnings date is November 5, 2026.

CLPT, US18507C1036, Illustration mit AI erstellt.

ClearPoint Neuro (ISIN US18507C1036) is facing a securities investigation announced by Pomerantz on October 13, 2026. The firm cited questions about statements by the company and its officers, while the underlying market reaction followed a September 29 clinical update involving development partner uniQure.

Three dates shape the story

On August 3, 2026, ClearPoint Neuro reported second-quarter revenue of USD 10.88 million, up 18.00 percent from USD 9.20 million in the same quarter of 2025, according to Yahoo Finance. The company also reported a net loss of USD 11.34 million for the quarter.

On September 29, 2026, uniQure disclosed that its Huntington's disease treatment did not achieve statistical significance on a primary clinical measure at 48 months. GlobeNewswire reported that ClearPoint Neuro stock fell USD 3.54, or 23.12 percent, to close at USD 11.77 that day.

On October 13, 2026, GlobeNewswire published Pomerantz's announcement that it is investigating potential securities-law claims involving ClearPoint Neuro and certain officers and directors. The announcement describes an investigation, not a finding of wrongdoing.

Revenue growth meets heavy investment

ClearPoint Neuro's second-quarter figures show a sharper contrast than the headline revenue growth alone. Cash and cash equivalents stood at USD 29.36 million on June 30, 2026, while operating cash flow was negative USD 7.02 million for the quarter, according to ClearPoint Neuro.

Management guided to 2026 revenue of USD 48.00 million to USD 52.00 million after prioritizing clinical support, regulatory expansion, capital equipment and focused ultrasound development. The Q2 call also described a 30,000-square-foot preclinical facility and a first statement of work for GLP services expected to be completed in the first half of 2027.

Next report date is November 5

ClearPoint Neuro's next earnings date is November 5, 2026, according to ToAlpha. That report will give investors a new checkpoint on revenue progression, cash use and the response to the September clinical setback.